Puma Biotechnology
PBYI
83 hedge funds and large institutions have $65.5M invested in Puma Biotechnology in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 29 reducing their positions, and 14 closing their positions.
698% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $134K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.31% less ownership
Funds ownership: 62.01% → 60.7% (-1.3%)
6% less funds holding
Funds holding: 88 → 83 (-5)
18% less capital invested
Capital invested by funds: $79.5M → $65.5M (-$14M)
28% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 29
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.68M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$532K |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
+$442K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$209K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$209K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.46M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.23M |
| 3 |
Renaissance Technologies
New York
|
-$518K |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$346K |
| 5 |
Goldman Sachs
New York
|
-$296K |
PBYI Hedge Fund Activity: Q3 2022 in Review
83 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2022, worth a combined $65.5M — down 18% from $79.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PBYI and 9 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 21 added.
The largest buyer was Millennium Management, adding an estimated $1.68M. The largest seller was Armistice Capital, cutting an estimated $1.46M.
- 83 institutional investors held Puma Biotechnology (PBYI) as of Q3 2022, down from 88 in Q2 2022.
- Funds reported $65.5M of Puma Biotechnology stock for Q3 2022, down 18% quarter-over-quarter.
- 9 funds opened new Puma Biotechnology positions in Q3 2022 and 14 closed out, a net change of -5 holders.
- The largest Puma Biotechnology buyer in Q3 2022 was Millennium Management, an estimated $1.68M added.
- The largest Puma Biotechnology seller in Q3 2022 was Armistice Capital, an estimated $1.46M sold.
Based on aggregated 13F filings for Q3 2022.